Table 2.
Baseline characteristics of the intent-to-treat (ITT) population and of patients who completed 4 years of natalizumab treatment
| Baseline characteristic | ITT population (n = 222) |
4-Year natalizumab completers (n = 105) |
|---|---|---|
| Age, mean (SD), years | 34.0 (9.0) | 34.1 (8.9) |
| Female, n (%) | 161 (72.5) | 74 (70.5) |
| Race and ethnicity, n (%)a | ||
| White, not Hispanic or Latino | 152 (68.5) | 71 (67.6) |
| Black or African American | 40 (18.0) | 24 (22.9) |
| Hispanic or Latino | 18 (8.1) | 6 (6.3) |
| Asian, American Indian, or Alaska Native | 3 (1.4) | 2 (1.9) |
| Time from diagnosis of MS, mean (SD), years | 1.6 (0.8) | 1.62 (0.8) |
| Time since MS symptom onset, mean (SD), years | 3.0 (2.6) | 2.83 (2.3) |
| Number of relapses in the past year | ||
| Mean (SD) | 1.4 (1.2) | 1.43 (0.9) |
| Median (range) | 1 (0–12) | 1.00 (0–4) |
| EDSS score | ||
| Mean (SD) | 2.0 (1.1) | 2.0 (1.0) |
| Median (range) | 2.0 (0–6.5) | 2.0 (0–4.0) |
| T2 lesion volume, median (range), cc | 3.9 (0–61.6)b | 4.5 (0–61.6)c |
| Number of Gd+ lesions, median (range) | 0 (0–71)b | 0 (0–71)c |
| Patients with no Gd+ lesions, n (%) | 114 (57.9)b | 50 (51.6)c |
| MS treatment history, n (%)d | 111 (50.0) | 45 (42.9) |
| Any interferon | 54 (48.6) | 27 (60.0) |
| Intramuscular interferon beta-1a | 29 (26.1) | 12 (26.7) |
| Subcutaneous interferon beta-1b | 10 (9.0) | 7 (15.6) |
| Subcutaneous interferon beta-1a | 19 (17.1) | 8 (17.8) |
| Glatiramer acetate | 50 (45.0) | 17 (37.8) |
| Dimethyl fumarate | 7 (6.3) | 3 (6.7) |
| Prednisolone | 7 (6.3) | 0 (0.0) |
| IV methylprednisolone | 6 (5.4) | 2 (4.4) |
| Teriflunomide | 3 (2.7) | 1 (2.2) |
| Methylprednisolone | 3 (2.7) | 0 (0.0) |
| Fingolimod | 1 (0.9) | 0 (0.0) |
| Medrol dose pack | 1 (0.9) | 0 (0.0) |
| Duration of MS treatment in those with history of use, weeks | ||
| Mean (SD) | 37.4 (29.1) | 40.45 (33.4) |
| Median (min, max) | 30.6 (0.4, 165.4) | 31.4 (1.1, 165.4) |
DMT disease-modifying therapy, EDSS Expanded Disability Status Scale, Gd+ gadolinium enhancing, IV intravenous, max maximum, min minimum, MS multiple sclerosis, SD standard deviation
aData were missing for 9 of 222 patients (4.1%)
bn = 197
cn = 97
dPatients may have reported prior use of > 1 treatment